Request Demo

Last update 25 Aug 2026

Cisplatin

Last update 25 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CACP, CDDP, CIS-DDP

+ [28]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [9]

Active Indication

Biliary Tract NeoplasmsSquamous Cell Carcinoma of Head and NeckMalignant Pleural Mesothelioma+ [72]

Inactive Indication

Adenocarcinoma of EsophagusAdvanced Bile Duct CarcinomaAdvanced Cervical Carcinoma+ [99]

Originator Organization

HQ Specialty Pharma Corp.

Privo Technologies, Inc.

Active Organization

CSPC Ouyi Pharmaceutical Co., Ltd.

Eleison Pharmaceuticals, Inc.

Eli Lilly & Co.

+ [26]

Inactive Organization

Hoffmann-La Roche, Inc.

Bayer AGEMD Serono Research & Development Institute, Inc.

+ [16]

License Organization

Chosa Oncology AB

UroGen Pharma Ltd.

Eleison Pharmaceuticals, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (19 Dec 1978),

Bladder CancerOvarian CancerTesticular Neoplasms

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaCl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS Registry15663-27-1

4,678

Clinical Trials associated with Cisplatin

NCT07639528

/ Not yet recruitingPhase 2IIT

Phase II, Open Label, Non-Randomized, Study of Optimal Preoperative Therapy for Intrahepatic Cholangiocarcinoma (OPTIC)

This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with intrahepatic cholangiocarcinoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine and/or targeted therapy with futibatinib before surgery may make the tumor smaller for resection and may help prevent the cancer from coming back. Patients whose molecular profiling test result show a genetic change called FGFR2 fusion, rearrangement, or activating mutation, receive immunotherapy, chemotherapy and targeted therapy while patients without a FGFR2 fusion, rearrangement, or activating mutation just receive immunotherapy and chemotherapy. Giving targeted therapy based on molecular profile test results prior to attempted resection for patients with intrahepatic cholangiocarcinoma that has a risk for either not being able to be removed or for coming back after it has been removed may help improve treatment outcomes in patients with resectable intrahepatic cholangiocarcinoma.

Start Date10 Dec 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT04910386

/ Not yet recruitingPhase 2

A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers

This is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancers

Start Date01 Jun 2027

Sponsor / Collaborator

3D Medicines (Sichuan) Co., Ltd.

NCT04595981

/ WithdrawnPhase 2IIT

Chemo-embolization for Head and Neck Cancer

The study will evaluate whether adjuvant chemo-embolization increases progression free and/or overall survival relative to standard of care radiation and chemo- and/or immunotherapy in cisplatin-ineligible head and neck cancer patients with an acceptable morbidity rate.

Start Date01 May 2027

Sponsor / Collaborator

The University of Alabama at Birmingham

100 Clinical Results associated with Cisplatin

100 Translational Medicine associated with Cisplatin

100 Patents (Medical) associated with Cisplatin

100,505

Literatures (Medical) associated with Cisplatin

01 Feb 2027·TISSUE & CELL

Yunnan Baiyao inhibits EBV-positive nasopharyngeal carcinoma via ferritinophagy-dependent ferroptosis

Article

Author: Yang, Lu ; Yang, Dongfan ; Zheng, Dayuan ; Yang, Yanchao ; Chu, Tong ; Liang, Shaokui ; Ma, Wenzhe ; Zhang, Kuanyun

BACKGROUND:

EBV-positive nasopharyngeal carcinoma frequently exhibits significant chemoresistance, posing a major challenge in clinical treatment. Yunnan Baiyao, a traditional Chinese patent medicine, has shown promise in antitumor research beyond its conventional hemostatic applications. This study investigated the efficacy of Yunnan Baiyao against EBV-positive nasopharyngeal carcinoma and explored the underlying molecular mechanisms of cell death.

METHODS:

Yunnan Baiyao-treated EBV-positive C666-1 and EBV-negative HK1/SUNE1 cells were subjected to Sulforhodamine B assay, colony formation assay, and C11-BODIPY/Fe²⁺ flow cytometry to verify antitumor activity and ferroptosis induction. Ferroptosis, autophagy, and ferritinophagy were confirmed via live-cell imaging, Transmission Electron Microscopy, and Western blotting. Specific inhibitors (Q-VD-Oph, Nec-1, etc.) validated the roles of apoptosis, necroptosis, and other pathways. Lentiviral NCOA4 knockdown verified its core function. Nude mouse xenograft models (with Liproxstatin-1 rescue and NCOA4-knockdown tumors) evaluated in vivo efficacy and dependence on ferroptosis/NCOA4.

RESULTS:

C666-1 cells (EBV-positive) are more resistant to cisplatin compared with SUNE1 and HK1 cells (both EBV-negative). Yunnan Baiyao exerted concentration- and time-dependent cytotoxicity on C666-1 cells. Notably, C666-1 cells were more sensitive to Yunnan Baiyao than SUNE1 cells. Yunnan Baiyao induced ferroptosis (not apoptosis/necroptosis/pyroptosis) with elevated lipid peroxidation, intracellular Fe²⁺ accumulation, and mitochondrial shrinkage. Yunnan Baiyao activated autophagic flux, and BAF (autophagy inhibitor) partially reversed ferroptosis. Yunnan Baiyao-induced cell death relied on NCOA4-mediated ferritinophagy; NCOA4 knockdown abrogated its effects in vitro. In vivo, Yunnan Baiyao significantly inhibited tumor growth, reversed by Lip-1 treatment or NCOA4 knockdown.

CONCLUSIONS:

Yunnan Baiyao overcomes chemoresistance in EBV-positive nasopharyngeal carcinoma by triggering NCOA4-mediated ferritinophagy-dependent ferroptosis. These findings provide a mechanistic foundation for further preclinical evaluation of Yunnan Baiyao as a candidate therapeutic strategy for chemoresistant nasopharyngeal carcinoma.

31 Dec 2026·CANCER BIOLOGY & THERAPY

Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN

Article

Author: Zhao, Wen ; Su, Yan ; Gao, Chao ; Cui, Chunying ; Duan, Chao ; Li, Lan ; Xue, Tianlin ; He, Sidou ; Liu, Shuguang ; Yue, Zhixia

BACKGROUND:

Current risk stratification for neuroblastoma (NB) relies on limited markers like MYCN amplification. Coilin, a key Cajal body component, regulates cellular processes. This study investigates whether coilin expression in bone marrow (BM) serves as a predictive biomarker for NB progression and elucidate its function in this disease.

METHODS:

The functions and molecular mechanisms of coilin were investigated by employing cell lines and animal models. Coilin mRNA levels in patient samples were measured by RT-PCR, and their relationships with clinicobiological characteristics and outcomes were analyzed.

RESULTS:

Cisplatin induced dramatic changes of coilin distribution and expression. Databases showed that high expression of coilin exerted predictive values for poor outcome in NB. Coilin promoted proliferation in vitro and in vivo. Knockdown of coilin expression inhibited cell migration and invasion, promoted apoptosis and increased the Cisplatin drug sensitivity. Moreover, coilin activates p53/p21 signaling pathway and was a direct target of MYCN. Analysis of BM samples demonstrated that high expression of coilin was obviously associated with adverse clinical biological features. Importantly, the levels of coilin at diagnosis were markedly higher than those at the time before maintenance treatment in the exact paired patients. Survival analysis presented that high coilin expression in BM is associated with poor prognosis.

CONCLUSIONS:

A novel and accessible coilin-targeted liquid biopsy method was developed, capable of detecting minimal residual disease (MRD) in early-stage NB and predicting disease progression and recurrence. Coilin was transcriptionally regulated by MYCN, offering potential avenues for the development of novel drugs or intervention strategies.

31 Dec 2026·RENAL FAILURE

Bergamottin pretreatment attenuates cisplatin-induced acute kidney injury in mice by inhibiting BACE-1-mediated ferroptosis

Article

Author: Yuan, Hui-feng ; Wang, Ya-jie ; Peng, Song ; Yang, Xue-ping ; Xu, You-song

Bergamottin is a natural furanocoumarin compound that possesses antioxidative and anticancer properties. However, the effect of bergamottin (BGM) on acute kidney injury (AKI) is unknown. Human renal tubular HK-2 cells and mice that received cisplatin were pretreated with BGM, after which their cytotoxicity and renal function were evaluated. BGM pretreatment alleviated cisplatin-induced cytotoxicity in vitro. Moreover, synergistic protection against cisplatin-induced cytotoxicity was observed when BGM and apoptosis, autophagy, or necrosis inhibitors were used together. There was no synergistic effect between BGM and the ferroptosis inhibitor. Furthermore, BGM significantly inhibited ferroptosis induction-induced damage to HK-2 cells. BGM pretreatment alleviated renal dysfunction and pathological damage by reducing renal proinflammatory cytokines and inhibiting inflammatory cell infiltration, lipid peroxidation and ferroptosis. Based on predictions by SwissTarget and molecular docking, BGM strongly interacts with residues of beta-secretase 1 (BACE-1) via hydrogen and hydrophobic interactions. Moreover, BACE-1 expression was significantly upregulated in the kidneys of AKI mice and HK-2 cells treated with cisplatin but markedly reduced following BGM intervention. Interestingly, siRNA-mediated silencing of BACE-1 in vitro substantially abolished the protective effect of BGM on HK-2 cells that received cisplatin. BGM effectively alleviated AKI by targeting BACE-1 to reduce ferroptosis, suggesting that BGM could be developed as a potential agent for managing and pretreating AKI.

1,527

News (Medical) associated with Cisplatin

11 hours ago

·www.prnewswire.com

Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer

SUMMIT, N.J., Aug. 25, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage pharmaceutical company advancing a transdermal curcuminoid therapeutic for pain and inflammation, today outlined converging preclinical and clinical evidence that its lead candidate, VAS-101 (Vasceptor®), targets a common inflammatory pain pathway across three distinct disease settings: sickle cell disease (SCD), chemotherapy-induced pain in cancer, and osteoarthritis (OA). Taken together, the company believes this body of work positions Vasceptor as a potential non-opioid advance in the treatment of chronic and acute pain. Continue Reading A Common Pathway Behind Very Different Pains Across distinct etiologies—including sickle cell crisis, chemotherapy-induced neuropathy, and inflammatory arthropathy—these disease models consistently converge on a singular molecular signature: IL-17-driven p38 MAPK signaling in neuronal and glial cells in the central nervous system. Post this Vasceptor is built on Vascarta's patented Vasporta™ gel-based delivery platform, which, combined with a small-molecule active pharmaceutical ingredient such as curcumin, is designed to cross the skin and reach plasma and circulating blood cells for both local and systemic effect — without the bioavailability limits of oral dosing or the burdens of intravenous administration [1]. A growing body of data suggests Vasceptor acts on a pain pathway shared across seemingly unrelated conditions: interleukin-17A (IL-17A) amplifying tumor necrosis factor-alpha (TNF-α) and p38 MAPK stress signaling, which drives central and peripheral nervous system sensitization to pain [2]. Because this cascade sits downstream of quite different initial triggers — hemolysis and hypoxia in SCD, chemotherapy-induced neurotoxicity in cancer (CIPN), and local joint inflammation in OA — a therapy that quiets it may relieve pain across all three indications: Sickle cell disease. In humanized sickle mice, transdermal curcumin reduced chronic mechanical and cold pain hypersensitivity, reduced mast cell activation, reduced axonal injury to dorsal root ganglion (DRG) neurons, and lowered multiple markers of red blood cell instability, hemolysis, and inflammation [1]. In a related mechanistic study, spinal IL-17A–TNF-α/p38 MAPK signaling was shown to drive acute pain behavior following incitement of hypoxia/reoxygenation in sickle mice; VAS-101 (transdermal curcumin) suppressed this cascade, reduced spinal microglial activation, and blunted the resulting hyperalgesia [2]. Chemotherapy-induced pain in cancer. In a mouse model of breast cancer, VAS-101 reduced mechanical, cold, and musculoskeletal hyperalgesia caused by cisplatin chemotherapy, while preserving cisplatin's antitumor efficacy. The formulation lowered spinal IL-17A, blocked cisplatin-driven p38 MAPK activation in DRG neurons and protected neuronal and mitochondrial structure — without blunting the chemotherapy's effect on tumor growth [3]. Osteoarthritis. In a randomized, double-blind, placebo-controlled Phase 1b trial in adults with knee osteoarthritis, VAS-101 produced a statistically significant reduction in KOOS pain scores and daily pain ratings versus placebo, with roughly 40% of participants reporting meaningful improvement within 28 days and a favorable tolerability profile [4]. Vascular and red blood cell effects. Complementary preclinical work shows VAS-101 preserves tissue oxygenation and microvascular perfusion during simulated vaso-occlusion [5], consistent with the company's broader view that Vasceptor's benefit in improving tissue oxygenation may extend beyond SCD to other conditions where hypoxia contributes to pain and tissue injury [6]. Leadership and Scientific Perspectives Dr. Kalpna Gupta, Professor, Division of Hematology/Oncology, University of California, Irvine, commented: "Across distinct etiologies—including sickle cell crisis, chemotherapy-induced neuropathy, and inflammatory arthropathy—these disease models consistently converge on a singular molecular signature: IL-17-driven p38 MAPK signaling in neuronal and glial cells in the central nervous system. Disrupting this shared pathway isn't just masking pain, it is delivering a disease-modifying targeted therapy rather than mere symptomatic pain relief." Dr. Joel Friedman, Vascarta Scientific Founder & Chief Scientific Officer, commented: "Vasporta was designed to solve a simple problem — facilitating a small molecule like curcumin through the skin and into circulation at levels oral dosing cannot achieve. Once VAS-101 is in circulation, it acts on the same inflammatory and oxidative pathways regardless of what set them in motion, whether sickle cell pain, chemotherapy-induced pain, or osteoarthritis pain. The targeting of the hard to disrupt cyclical interplay of activated mast cells, microglia and the IL17 pathways has very general implications for both pain and neuro-inflammatory diseases." Dr. Richard Prince, Vascarta Chairman, CEO & President, commented: "Pain relief that doesn't rely on opioids remains one of the largest unmet needs in medicine. We believe the data across these three indications support Vasceptor's (VAS-101) potential as a genuine advance — a single, safe, transdermal platform addressing a shared biological driver of pain potentially reducing the need for disease-specific pain treatments. We look forward to advancing our IND submissions and continuing this work with our collaborators." About VAS-101 (Vasceptor®) VAS-101 is a topical curcumin formulation employing Vascarta's patented Vasporta™ transdermal delivery technology to increase bioavailability. VAS-101 is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (Bronx, New York, USA). Curcumin is a well-studied molecule with potent anti-inflammatory, antioxidant, and analgesic properties arising in part from its pleiotropic targeting of multiple contributing signaling pathways. Poor oral bioavailability of curcumin has limited its clinical effectiveness. Transdermal and transmucosal delivery of curcumin via VAS-101 overcomes the limitations of oral delivery and promotes enhanced therapeutic efficacy of curcumin and many other potential but hard-to-deliver small molecule therapeutics. About Vascarta Vascarta is a clinical stage company innovating treatments for chronic diseases via transdermal and transmucosal loading of drugs into circulating blood cells for targeted anti-inflammatory activity. More information can be found at . Investor Contact Dr. Richard Prince, Chairman, CEO & President — [email protected] Media Contact David Hymson, Communications — [email protected] References 1. Goel Y, Arellano MA, Fouda RT, et al. Targeting sickle cell pathobiology and pain with novel transdermal curcumin. PNAS Nexus. 2025;4(2):pgaf053. 2. Goel Y, Argueta DA, O'Daniel K, Mireles C, Lomeli RA, Prince R, Friedman J, Gupta K. Neuroimmune signaling through spinal IL-17–TNF-α/p38 MAPK drives acute pain in sickle cell disease. J Sickle Cell Dis. 2026;3(Suppl 1):yoag020.003. 3. Goel Y, Mireles C, Ordaz D, O'Daniel K, Peterson KA, Lomeli N, Lomeli R, Bota DA, Friedman J, Gupta K. Novel transdermal curcumin (VAS-101) attenuates cisplatin-induced neuropathy in a mouse model of breast cancer. Presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, Poster #5216. 4. Lopresti AL, Antony B, Smith SJ. The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study. Front Pain Res. 2026;7:1789088. 5. Nugent WH, Prince R, Friedman J, Song BK. Transdermal curcumin gel (VAS-101 drug candidate) improves the microcirculation and tissue oxygenation in a rat model of sickle cell vaso-occlusive episode. J Sickle Cell Dis. 2026;3(1):yoag034. 6. Vascarta Inc. Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease. PR Newswire. August 20, 2026. SOURCE Vascarta Inc. 21% more press release views with Request a Demo

Clinical ResultPhase 1

24 Aug 2026

·www.prnewswire.com

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure Aug. 20, 2026 -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. In a related equity investment agreement, UroGen will invest up to $7 million in the equity securities of IntraGel, which will support the Phase 2 clinical development of TumoCure, IntraGel's investigational therapy for advanced head and neck cancer. Under the related Option Agreement, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure following IntraGel's completion of a Phase 2 clinical study. In addition, UroGen gains access to IntraGel's proprietary SRGel™ platform, a biodegradable sustained-release formulation technology designed for localized drug delivery, through a research license and options to obtain an exclusive, worldwide license to develop and commercialize up to three additional oncology products combining the SRGel platform with compounds to be designated by UroGen. "UroGen's leadership in localized oncology therapies and commercial-stage experience make them an ideal collaborator to help advance the SRGel platform and accelerate the development of TumoCure," said Peter Siman, Ph.D., Chief Executive Officer and Co-Founder, IntraGel Therapeutics. "We see this collaboration as an important validation of our SRGel platform and the clinical potential of our lead investigational product, TumoCure, while creating a strong pathway to accelerate development across multiple oncology indications." "This agreement represent an important step in expanding UroGen's oncology pipeline and our technological capabilities," said Liz Barrett, President and Chief Executive Officer of UroGen Pharma. "IntraGel's biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure, we believe the SRGel platform could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time." Dr. Siman added, "In parallel, we are continuing to advance additional therapeutic candidates in our pipeline based on the broadly applicable SRGel platform including our internally developed IG-003 with GLP-1 analogues for weight management, and monoclonal antibody and peptide programs developed through ongoing collaborations." SRGel is a biodegradable depot technology designed to enable sustained release of therapeutic agents over extended periods. The platform's flexibility supports multiple therapeutic modalities and indications. In oncology, SRGel has potential applicability across a broad range of solid tumor settings, including bladder, skin, brain, gastrointestinal and testicular cancers, creating opportunities for future localized oncology treatments beyond the initial collaboration programs. TumoCure is an investigational cisplatin product formulated with IntraGel's proprietary SRGel platform, designed to enable prolonged localized drug exposure while limiting systemic exposure. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Phase 1b clinical data demonstrated that TumoCure was generally safe and well tolerated, showed low systemic cisplatin exposure, and provided early indications of anti-tumor activity in a heavily pretreated patient population, including patients with cisplatin treatment-resistant disease1. Investigators also reported improvements in tumor-related symptoms in certain patients. These findings support continued clinical development of TumoCure and further expansion of the SRGel platform as a potential approach for sustained local therapy across additional solid tumors while minimizing systemic exposure. SRGel is IntraGel's proprietary injectable hydrophobic gel-like drug delivery platform designed to enable sustained, tailored drug release. Built on a proprietary water-free and solvent-free fatty-acids based polymer matrix, SRGel is engineered to provide controlled, and prolonged release of therapeutics agents following a single administration, with applicability for both localized delivery at the target site and sustained systemic exposure. The technology is designed, when injected intratumorally, to maintain high local drug concentrations while minimizing systemic exposure and associated toxicities. SRGel is compatible with a broad range of therapeutic modalities, including small molecules, peptides and biologics, and may be applicable across therapeutic areas and indications, including weight loss management and inflammatory diseases. TumoCure is IntraGel's lead product candidate and the first clinical application of the SRGel platform. TumoCure consists of cisplatin incorporated into the SRGel biodegradable matrix and is administered as a single intratumoral injection. The investigational therapy is designed to provide sustained delivery of cisplatin directly within tumor tissue over several months while limiting systemic exposure. TumoCure is Phase 2-ready and is being developed for patients with locally advanced, inoperable head and neck cancers, who are ineligible for systemic cisplatin-based chemoradiation. IntraGel is pursuing development through the U.S. Federal Drug Administration (FDA)'s 505(b)(2) regulatory pathway and believes the technology may have future applicability across additional solid tumor indications, including lung, brain, gastrointestinal, ovarian and testicular cancers. IntraGel develops long-acting injectable therapies that can replace daily or weekly dosing with a single administration, or convert large, painful injections into small-volume, highly concentrated doses. SRGel is IntraGel's long-acting injectable platform designed to support safer, more durable treatment options across multiple therapeutic areas and modalities, including small molecules, peptides, and biologics. IntraGel's lead product candidate based on the SRGel platform, TumoCure, for the treatment of head and neck cancer is Phase 2-ready. In addition, SRGel was shown in both in vivo and in vitro studies to deliver stable, long-acting exposure with GLP-1 analogues, monoclonal antibodies and peptides. IntraGel's technology is based on the research of Prof. Avi Domb, the School of Pharmacy, Institute for Drug Research at the Hebrew University of Jerusalem and IntraGel's Scientific Founder and Chief Scientist. The Company was established as part of NGT, a unique VC and technology incubator dedicated to investing in visionary entrepreneurs from promising early-stage healthcare startups that bring positive social impact. The content above comes from the network. if any infringement, please contact us to modify.

License out/inASCO

24 Aug 2026

·www.biospace.com

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a strategic Option and Research License Agreement (the Option Agreement) and a related equity investment agreement (the Investment Agreement) with IntraGel Therapeutics, Ltd. (IntraGel). The Option Agreement includes two strategic components. First, UroGen gains access to IntraGel's proprietary SRGel platform, a biodegradable, sustained-release formulation technology designed for localized drug delivery, through a research license and options to obtain an exclusive, worldwide license to develop and commercialize up to three additional oncology products combining the SRGel platform with compounds to be designated by UroGen. Second, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure, IntraGel’s investigational therapy for advanced head and neck cancer, following IntraGel's completion of a Phase 2 clinical study. "This Option Agreement represents an important step in expanding UroGen's oncology pipeline and technological capabilities," said Liz Barrett, President and Chief Executive Officer of UroGen. "IntraGel's biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure following a Phase 2 clinical study, we believe the SRGel technology could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time." In connection with the Option Agreement, UroGen has also entered into an Investment Agreement with IntraGel, pursuant to which UroGen will invest up to $7 million in the equity securities of IntraGel. SRGel is a biodegradable depot technology designed to enable sustained local release of therapeutic agents over extended periods. The platform's flexibility supports multiple therapeutic modalities and has potential applicability across a broad range of solid tumor settings. “UroGen’s leadership in localized oncology therapies and commercial-stage experience make them an ideal partner to help advance the SRGel platform and accelerate the development of TumoCure,” said Peter Siman, Ph.D., Chief Executive Officer and Co-Founder of IntraGel. “We see in this collaboration an important validation of the SRGel platform and the clinical potential of our lead product candidate, TumoCure, while creating a strong pathway to accelerate development across multiple oncology indications.” TumoCure is an investigational cisplatin treatment formulated with IntraGel’s proprietary SRGel platform, designed to enable prolonged localized drug exposure while limiting systemic exposure. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, early clinical data (N=8) showed that TumoCure was generally well tolerated in Phase 1b patients, showed low systemic cisplatin exposure, and provided early indications of anti-tumor activity in a heavily pretreated patient population, including patients with cisplatin treatment-resistant disease. Investigators also reported improvements in tumor-related symptoms in certain patients. These findings support continued clinical development of TumoCure and further expansion of the SRGel platform as a potential approach for sustained local therapy across additional solid tumors with the goal of minimizing systemic exposure. About SRGel SRGel is IntraGel’s proprietary injectable hydrophobic gel-like drug delivery platform designed to enable sustained drug release directly within solid tumors. Built on a proprietary water-free and solvent-free fatty-acids based polymer matrix, SRGel is engineered to provide controlled, and prolonged release of therapeutic agents following a single administration, with applicability for both localized delivery at the target site and sustained local exposure. The technology is designed, when injected intratumorally, to maintain high local drug concentrations while minimizing systemic exposure and associated toxicities. SRGel has shown early indications of compatibility with a broad range of therapeutic modalities, including small molecules, peptides and biologics, and may be applicable across various therapeutic areas and indications, including weight loss management and inflammatory diseases. About TumoCure TumoCure is IntraGel’s lead product candidate and the first clinical application of the SRGel platform. TumoCure consists of cisplatin incorporated into the SRGel biodegradable matrix and is administered as a single intratumoral injection. The investigational therapy is designed to provide sustained delivery of cisplatin directly within tumor tissue over several months while limiting systemic exposure. TumoCure is Phase 2-ready and is currently being developed for patients with locally advanced, inoperable head and neck cancers, who are ineligible for systemic cisplatin-based chemoradiation. IntraGel is pursuing development through the U.S. Federal Drug Administration (FDA)’s 505(b)(2) regulatory pathway and believes the technology may have future applicability across additional solid tumor indications, including lung, brain, gastrointestinal, ovarian and testicular cancers. About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel ® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X, @UroGenPharma. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential benefits of the Option Agreement with IntraGel; UroGen’s plans to evaluate, develop and potentially commercialize oncology products utilizing the SRGel platform; the potential therapeutic applications of the SRGel platform, including its ability to enable sustained local drug release, maintain high local drug concentrations and limit systemic exposure; the potential applicability of the SRGel platform across multiple therapeutic modalities, therapeutic areas and solid tumor settings, including weight loss management and inflammatory diseases; the intended performance and clinical development of TumoCure, including its potential to provide sustained delivery of cisplatin within tumor tissue while limiting systemic exposure; expectations regarding the continued clinical development of TumoCure, including the planned Phase 2 clinical study; IntraGel’s pursuit of the FDA’s 505(b)(2) regulatory pathway for TumoCure; the potential future applicability of TumoCure across additional solid tumor indications, including lung, brain, gastrointestinal, ovarian and testicular cancers; and the potential of UroGen’s RTGel platform technology to improve the therapeutic profiles of existing drugs and enable longer exposure of urinary tract tissue to medications. Words such as “anticipate,” “believe,” “could,” “may,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: preliminary clinical results may not be indicative of results that may be observed in the future; potential safety and other complications related to UroGen’s products and product candidates, as well as the product candidates covered by the Option Agreement; there is no guarantee that the Option Agreement will yield any product candidates that UroGen determines have strategic value, and even if UroGen elects to exercise its option to obtain an exclusive license to one or more product candidates, there is no guarantee that any such products will receive regulatory approval; risks related to our and our licensors’ ability to protect our respective patents and other intellectual property, including the fact that UroGen’s or its licensors’ pending patent applications may not be successful, and in such event, the duration of intellectual property protection would be more limited; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and UroGen’s products and product candidates may not perform as expected; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. These and other risks and uncertainties are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission on August 5, 2026. In light of these risks and uncertainties, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@UroGen.com 609-460-3588 ext. 1093 MEDIA CONTACT: Cindy Romano Director, Corporate Communications cindy.romano@UroGen.com 609-460-3566 ext. 1083

Phase 1License out/inASCOPhase 2Clinical Result

100 Deals associated with Cisplatin

External Link

KEGG	Wiki	ATC	Drug Bank
D00275	Cisplatin	L01XA01	DB00515

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Biliary Tract Neoplasms	Japan	Nippon Kayaku Co., Ltd.	22 Feb 2012
Squamous Cell Carcinoma of Head and Neck	Brazil	Libbs Farmacêutica Ltda.	22 Jan 2007
Malignant Pleural Mesothelioma	Japan	Nippon Kayaku Co., Ltd.	04 Jan 2007
Childhood Malignant Solid Neoplasm	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Bone Cancer	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Endometrial Carcinoma	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Germinoma	Japan	Nippon Kayaku Co., Ltd.	31 May 2004
Hepatocellular Carcinoma	Japan	Nippon Kayaku Co., Ltd.	29 Jan 2004
Osteosarcoma	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Small Cell Lung Cancer	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Solid tumor	China	Dezhou Deyao Intelligent Pharmacy Co., Ltd.	01 Jan 1995
Solid tumor	China	Kunming Guiyan Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Dezhou Bocheng Pharmaceutical Technology Co., Ltd.	01 Jan 1995
Solid tumor	China	Qilu Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Yunnan Phytopharmaceutical Co. Ltd.	01 Jan 1995
Stomach Cancer	Japan	Nippon Kayaku Co., Ltd.	03 Jun 1990
Esophageal Carcinoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Neuroblastoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Uterine Cervical Cancer	Japan	Nippon Kayaku Co., Ltd.	30 May 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscle Invasive Bladder Carcinoma	Phase 3	Australia	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Brazil	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Canada	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	France	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Italy	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Netherlands	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Spain	AstraZeneca PLC	15 May 2025
Squamous cell carcinoma of the oral cavity	Phase 3	United States	Privo Technologies, Inc.	07 Nov 2024
Fallopian Tube Carcinoma	Phase 3	United States	GSK Plc	08 Mar 2024
Primary peritoneal carcinoma	Phase 3	United States	GSK Plc	08 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03410030 (AA NABPLAGEM, CTgov)	Phase 1/2	Pancreatic Ductal Adenocarcinoma \| Neoplasm Metastasis \| Metastatic Pancreatic Cancer	17	Ascorbic Acid (Ascorbic Acid 25 g/m^2)	wxctdshvuj(sugovvqjtz) = uzsbxavkqq rtutpcvpzv (mtsnhlkvun, 66.3) View more	-	23 Jul 2026
				Ascorbic Acid (Ascorbic Acid 37.5 g/m^2)	wxctdshvuj(sugovvqjtz) = jlkyebsjbh rtutpcvpzv (mtsnhlkvun, 62.0) View more
NCT04669197 (CTgov)	Phase 2	Pancreatic adenocarcinoma \| Pancreatic Ductal Adenocarcinoma \| Locally Advanced Pancreatic Adenocarcinoma	19	Paclitaxel protein bound+Hydroxychloroquine+Gemcitabine+cisplatin	diknwofgwy = riqenpjzkj jzxymdyqwm (axnwrsuwlo, khgcsdchjt - rpvkhvmugq) View more	-	21 Jul 2026
TOPAZ-1 (ESMO_GI2026 \| ESMO_GCC2026)	Not Applicable	Advanced biliary tract cancer First line	1,358	Cisplatin, gemcitabine, and durvalumab (TOPAZ-1-in)	reqfrvvfjl(fqqiitxnuo) = TOPAZ-1-out patients experienced no significant increase in adverse events compared with the TOPAZ-1-in group. splfqztkor (rnesfbtida ) View more	Positive	02 Jul 2026
				Cisplatin, gemcitabine, and durvalumab (TOPAZ-1-out)
NCT04924101 (KEYNOTE-B99, CTgov)	Phase 2	Extensive stage Small Cell Lung Cancer	122	MK-4830+Etoposide+Carboplatin+cisplatin+Pembrolizumab (Pembrolizumab + MK-4830 + Chemotherapy)	jhevffkhiu = hrkdhdakhi qyzsiefpjc (yrjlacqoyj, evwbadoecf - lnazhvuuim) View more	-	01 Jul 2026
				Etoposide+Boserolimab+Carboplatin+cisplatin+Pembrolizumab (Pembrolizumab + Boserolimab + Chemotherapy)	jhevffkhiu = jtfnvzgxwl qyzsiefpjc (yrjlacqoyj, hgzrsgryts - dcncydbnld) View more
ASCO_Breakthrough2026	Not Applicable	Esophageal Carcinoma First line	61	modified docetaxel, cisplatin, and fluorouracil (mDCF)	ivuwvizhvb(entbxjdcws) = evjpbrdddr zjbjyxwsji (nzakejnyjj ) View more	Positive	25 Jun 2026
ASCO2026	Not Applicable	Pancreatic Cancer First line	138	PAXG (cisplatin, nab-paclitaxel, capecitabine and gemcitabine)	rkejegwiqi(jhypkjjojx) = docbbhjduu yqqtmxiclw (yhiyxtvtus ) View more	Positive	29 May 2026
				mFOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin)	rkejegwiqi(jhypkjjojx) = ckzqhgrmjx yqqtmxiclw (yhiyxtvtus ) View more
NCT01970722 (ASCO2026)	Phase 1	Ovarian Cancer	41	Cisplatin 75 mg/m2 (good responder)	wtazrppyjy(irwpdbbyko) = Patients with peritoneal-only recurrence had higher SBS15 (DNA mismatch repair) mutational burden compared to patients with extraperitoneal recurrence (p=0.048) gvjiysjcqh (ktkkmhrvml ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Locally Advanced Squamous Cell Carcinoma Neoadjuvant	113	Neoadjuvant albumin-bound paclitaxel plus cisplatin or carboplatin combined with a PD-1 inhibitor	ilocdkzowi(udjilmstud) = cptexhdstv ywyzzinrke (oaersdppnd ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Penile Neoplasms Neoadjuvant	58	TIP	wfpdqxknec(zycftoakon) = oyverevaqw uqhoqsiplq (spvfjsytvn ) View more	Positive	29 May 2026
				Platinum doublet	wfpdqxknec(zycftoakon) = ajajlnspab uqhoqsiplq (spvfjsytvn ) View more
ASCO2026	Not Applicable	Recurrent Head and Neck Carcinoma	180	Cisplatin + 5-fluorouracil	sexphyhmcm(ndkgmxnsdn) = adverse events including vomiting, renal insufficiency, fever, bone marrow suppression, hearing loss, and skin rashes were more frequent with CF sowepovxhq (ppayqszigv ) View more	Positive	29 May 2026
				Gefitinib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis